Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension

被引：0
|
作者：
Dardi, F. [1 ]
Guarino, D. [2 ]
Ballerini, A. [2 ]
Magnani, I. [2 ]
Donato, F. [2 ]
Bertozzi, R. [2 ]
Martini, G. [2 ]
Manes, A. [2 ]
Galie', N. [2 ]
Palazzini, M. [2 ]
机构：
[1] Inst Cardiol, Bologna, Italy
[2] Univ Bologna, CardioThoracicVasc Dept, Alma Mater Studiorum, IRCCS St Orsola Hosp, Bologna, Italy
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EFFICACY COMPARISON OF PROSTACYCLIN ANALOGUE AND PROSTACYCLIN RECEPTOR AGONIST AS THIRD LINE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION
    Dardia, Fabio
    Martini, Giulia
    Guarino, Daniele
    Magnani, Ilenia
    Rotunno, Mariangela
    Ballerini, Alberto
    Bertozzi, Riccardo
    Donato, Federico
    Manes, Alessandra
    Palazzini, Massimiliano
    Galie, Nazzareno
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [2] A Novel, Inhaled Prostacyclin Receptor Agonist For The Treatment Of Pulmonary Arterial Hypertension
    Rowlands, D. J.
    Coote, K.
    Bonneau, O.
    Choy, K.
    Duggan, N.
    Thomas, M.
    LeBlanc, C.
    Charlton, S.
    Healy, M.
    Grant, S.
    Strieter, R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [3] The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension
    Pedersen, Mia Lindegaard
    Krueger, Marcus
    Grimm, Daniela
    Infanger, Manfred
    Wehland, Markus
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (01) : 32 - 42
  • [4] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Simonneau, Gerald
    Torbicki, Adam
    Hoeper, Marius M.
    Delcroix, Marion
    Karlocai, Kristof
    Galie, Nazzareno
    Degano, Bruno
    Bonderman, Diana
    Kurzyna, Marcin
    Efficace, Michela
    Giorgino, Ruben
    Lang, Irene M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) : 874 - 880
  • [5] Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
    Asaki, Tetsuo
    Kuwano, Keiichi
    Morrison, Keith
    Gatfield, John
    Hamamoto, Taisuke
    Clozel, Martine
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7128 - 7137
  • [6] Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
    Baker, William L.
    Darsaklis, Konstadina
    Singhvi, Aditi
    Salerno, Edward L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2017, 51 (06) : 488 - 495
  • [7] Pulmonary arterial hypertension: selexipag Selective prostacyclin receptor agonist orally
    Lobo Marquez, Lilia Luz
    Bevacqua, Raul J.
    [J]. INSUFICIENCIA CARDIACA, 2019, 14 (01) : 34 - 44
  • [8] Discovery of the first, designed for inhalation, prostacyclin receptor agonist for pulmonary arterial hypertension
    Healy, Mark
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [9] Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review
    Honorato Perez, Jesus
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (07) : 753 - 762
  • [10] Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue
    Vizza, CD
    Sciomer, S
    Morelli, S
    Lavalle, C
    Di Marzio, P
    Padovani, D
    Badagliacca, R
    Vestri, AR
    Naeije, R
    Fedele, F
    [J]. HEART, 2001, 86 (06) : 661 - 665
12345